Furthermore, key risk factors for NAFLD, including insulin insensitivity, obesity, and dyslipidemia, are alleviated by FGF-21, and FGF-21 has been reported to reverse liver steatosis while counteracting obesity and enhancing insulin sensitivity [20]. This evidence concerns the gene FGF21 and obesity disorder.